UEGweek 2025

New rumours about small molecules

AI AI captain! - AI improves histological diagnostics

IL-23 inhibition: sc is nice, oral is better ?!

New molecules in moderate to severe UC: obefazimod &…

Pregnancy and family planning in IBD

Are JAK inhibitors better than their reputation?

Fistulizing perianal disease - still challenging!

Complete disease clearence - the quest for the optimal…

Modifying the diet does have an impact on IBD risk!

Timing is everything - surgical intervention in CD

Do biologics need an iv induction?

T2T in UC - first piece of restrospective evidence

Finally time to stop the automatic continuation of…

JAKis may be safer than you probably think they are!

T2T nella CU – prime evidenze retrospettive

Endlich Zeit das automatisierte 5-ASA Weiterführen zu…

Effektivität der s.c. Induktion mit Guselkumab bei UC

Efficacy of Guselkumab in CD patients who lost response…

Patients with early Crohn’s disease on adalimumab: can…

Injecting in fistulas: the never ending story?

Early treatment with adalimumab does not allow for…

Can we stop Adalimumab in CD patients achieving…

Efficacy of guselkumab in patients with inadequate…

Therapy sequence: guselkumab is possible after…

Perianal CD - it's associated with low infliximab…

Is it possible to stop anti-TNF treatment in early CD…

To stop or not to stop? That is the question (in…

Czy przerywać skuteczne leczenie u pacjentów z chorobą…

Ασθενείς με πρόσφατη έναρξη νόσου του Crohn σε…

הזרקת תאים לפיסטולה במחלת קרוהן- הסיפור שאינו נגמר?

Therapiesequenz: Guselkumab nach Ustekinumab-Versagen…

Efficacia di Gusekumab in pazienti affetti da malattia…

Possiamo sospendere Adalimumab in pazienti affetti da…

Peut-on arrêter un anti-TNF dans la maladie de Crohn…

B-cell depletion in refractory ulcerative colitis –…

Oral mufemilast, a PDE4 inhibitor, for moderate to…

Go for oral anti-α4β7!

CAR-T cells in refractory UC – a new option for the…

IL-23 blockade now also oral

Icotrokina - a new oral drug for blocking IL-23

B-Zell-Depletion bei refraktärer Colitis Ulcerosa -…

Obefazimod - Une nouvelle classe thérapeutique pour la…

IL-23 Blockade jetzt auch oral

Puntare sugli anti-α4β7 orali!

Mufemilast, αναστολέας της PDE4, για θεραπεία από του…

Short-term (8 weeks) efficacy & safety of obefazimod in…

Histo-endoscopic endpoint in long-term extension of…

Real-world short-term efficacy and safety of…

Etrasimod in mild to moderate UC

Obefazimod induction therapy is effective and well…

Obefazimod in moderate to severe UC

Efectividad y seguridad en vida real a corto plazo de…

Etrasimod nella colite ulcerosa da lieve a moderata

Obefazimod nella colite ulcerosa da moderata a grave

Eficacia y seguridad a corto plazo (8 semanas) de…

Obefazimod-Induktionstherapie ist effektiv und gut…

JAK-Inhibitoren sind vielleicht sicherer als Sie…

Μακροχρόνια αποτελεσματικότητα της ουστεκινουμάμπης σε…

Risankizumab in Crohn’s disease - real-world data…

Ustekinumab in perianal Crohn’s disease

Guselkumab sc en enfermedad de crohn con respuesta…

Dane typu real-life a badania kliniczne risankizumabu w…

Steroid-sparing effect of upfront Vedolizumab in…

When nanoparticles calm down celiac-specific T-cells

IBD outcome in a large national cohort from spain

New insights from the GEM trail

Selection criteria for randomized clinical trials in…

Let's go green! ecological effect of patient monitoring

IUS as a patient- and environmental-friendly tool in…

Looking for the black sheep pathways

Vedolizumab - another option for JAKi-induced…

Real-life vs clinical trials IBD patients access to…

Sigmoid volvulus: an old problem, still waiting for…

AI-endoscopy ready - is it a game changer?

Reassuring safety signals of JAKis in pregnant IBD…

Eosinophilic esophagitis doesn’t seem to increase the…

Auf der Suche nach den schwarzen Pathway-Schafen

פתלת הפרשדון....בעיה מוכרת שעדין מחכה לפתרון

Eosinophile Ösophagitis ist kein Risikofaktor für ein…

Co ma wspólnego USG jelit w IBD z ekologią?

Critères de sélection des essais cliniques randomisés…

Risparmio di steroidi in pazienti con colite indotta da…

JAK-Inhibitoren und Schwangerschaft bei CED

Segnali si sicurezza rassicuranti in donne affette da…

Πρόσβαση σε προχωρημένες θεραπείες καθημερινών ασθενών…

Vedolizumab - eine zusätzliche Therapieoption bei…

Verso il verde! L’impatto ecologico del monitoraggio…